• Explore /
  • Poster
  • / First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Debashis Sarker

King's College London, London, United Kingdom

Debashis Sarker , Mikael Sodergren , Elizabeth Ruth Plummer , Bristi Basu , Tim Meyer , Kai-Wen Huang , T.R. Jeffry Evans , Duncan Spalding , Yuk Ting Ma , Daniel H. Palmer , Cheng Ean Chee , David James Pinato , Vikash Reebye , Daniel McVeigh , Nina Raulf , Jenni Vasara , Pinelopi Andrikakou , Robert Habib , David Blakey , Nagy A. Habib

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02716012

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 554)

Abstract #

554

Poster Bd #

D15

Abstract Disclosures

Similar Posters

First Author: Debashis Sarker

First Author: Debashis Sarker

First Author: Jinpeng Li

First Author: Danni Li